Navigation Links
GlaxoSmithKline’s Tykerb is to Be Started Earlier in Breast Cancer, Study Find

London: Statistics from a Phase III study has shown that GlaxoSmithKline's Tykerb along with Roche's Xeloda is far better than Xeloda alone in women with HER2// positive advanced breast cancer, where the disease had progressed despite previous therapy involving Herceptin.

Basis the findings, researchers opined that, Tykerb should be checked out for its use during the early treatment of HER2 positive breast cancer.

"Patients with advanced or metastatic HER2 positive breast cancer have limited options once their cancer has progressed on trastuzumab and standard initial chemotherapy regimens. There has been a clear need for alternative treatments to help women with metastatic breast cancer in this advanced setting. Lapatinib combined with capecitabine has demonstrated superior efficacy over capecitabine alone in this group of patients and we look forward to it being made available to women suffering from this devastating disease," said lead investigator Charles Geyer, Director of Breast Medical Oncology at Allegheny General Hospital, Pittsburgh, Pennsylvania, U.S.

Women suffering HER2 positive breast cancer carry an enhanced risk of advancement of disease and death as against women suffering tumors.

Page: 1

Related medicine news :

1. GlaxoSmithKline’s Epilepsy Drug given the Green Signal by FD
2. GSK Seeks Permission to Market Breast Cancer Pill Tykerb
3. International Osteoporosis Research Centre To Be Started In India.
4. New Test Can Detect Breast Cancer 8 Years Earlier
5. Earlier the better to start healthy diets
6. Gum Disease Affects Diabetic Children Earlier Than Anticipated
7. Earlier Introduction of Solid Foods in Infants Could Prevent Wheat Allergy
8. Earlier the Cochlear Implants Used Better the Speech
9. Profiling of Cancer Genes May Lead to Earlier Detection Human Cancers
10. Hay Fever Season may Begin Earlier, Warns Experts
11. Diabetes Risk Factors Develop Earlier in Women Than Men
Post Your Comments:

(Date:11/29/2015)... Ca (PRWEB) , ... November 29, 2015 , ... Khanna ... American Board of Ophthalmology on November 25th 2015. Peer Certification by the ... field of his specialty. Certification in Ophthalmology is first obtained after the completion of ...
(Date:11/29/2015)... ... November 29, 2015 , ... Doctors who missed a case of mesothelioma ... signs of mesothelioma and push for a diagnosis, especially in people exposed to asbestos. ... here to read it now. , Researchers at Gifu Prefectural Tajimi Hospital ...
(Date:11/29/2015)... Chicago, IL (PRWEB) , ... November 29, 2015 , ... ... website, In addition starting on Black Friday Target is offering a “Buy ... only. This is a rare opportunity to purchase IguanaMed at a discounted price. ...
(Date:11/28/2015)... ... November 28, 2015 , ... StatRad ... has added Chris Hafey and Claude Hooton to its board of directors. The ... North America (RSNA) 2015 Annual Meeting and continues to strategically transform its focus ...
(Date:11/28/2015)... (PRWEB) , ... November 28, 2015 , ... Trying to ... has created the COUCH BUDDY. "I conceived of this design due to personal experience ... for couch users. It promotes relaxation and convenience, as well as increases support. It ...
Breaking Medicine News(10 mins):
(Date:11/29/2015)... , Nov. 29, 2015 CIVCO ... guidance technology at the Radiological Society of ... Chicago November 29 – ... is designed to offer customers unrivaled versatility, enhanced ... --> ...
(Date:11/27/2015)... November 27, 2015 Ein ... fortgeschrittenem Krebs.   --> Ein neuer ... Krebs.   --> Ein neuer ... Krebs.   Clinical Cancer Research ... Clinical Cancer Research vom 6. November 2015 ...
(Date:11/26/2015)... , November 27, 2015 ... --> --> ... emergency response system (PERS) market ... for 5 years with APAC ... expected to see a high ...
Breaking Medicine Technology: